Sodium Polystyrene Sulfonate
Active ingredient: Sodium Polystyrene Sulfonate
In short: Sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. Limitation of Use: Sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action
What is Sodium Polystyrene Sulfonate used for?
Sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia.
Limitation of Use:
Sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action
Sodium Polystyrene Sulfonate dosage
.
Administer sodium polystyrene sulfonate at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation
The intensity and duration of therapy depend upon the severity and resistance of hyperkalemia.
Oral
The average total daily adult dose of sodium polystyrene sulfonate is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily.
Rectal
The average adult dose is 30 g to 50 g every six hours.
Prepare suspension fresh and use within 24 hours.
Do not heat sodium polystyrene sulfonate as it could alter the exchange properties of the resin.
One level teaspoon contains approximately 3.5 g of sodium polystyrene sulfonate and 15 mEq of sodium.
Oral Suspension
Suspend each dose in a small quantity of water or syrup, approximately 3 to 4 mL of liquid per gram of resin. Administer with patient in an upright position .
Enema
After an initial cleansing enema, insert a soft, large size (French 28) rubber tube into the rectum for a distance of about 20 cm, with the tip well into the sigmoid colon, and tape in place.
Administer as a warm (body temperature) emulsion in 100 mL of aqueous vehicle and flush with 50 to 100 ml of fluid. A somewhat thicker suspension may be used, but do not form a paste.
Agitate the emulsion gently during administration. The resin should be retained for as long as possible and follow by a cleansing enema with a nonsodium containing solution. Ensure an adequate volume of cleansing solution (up to 2 liters) is utilized.
How to take Sodium Polystyrene Sulfonate — instructions & advice from the label
Drug Interactions
Advise patients who are taking other oral medication to separate the dosing of sodium polystyrene sulfonate by at least 3 hours (before or after) [see Dosage and Administration (2.1), Warnings and Precautions (5.5), and Drug Interactions (7.1)]
Rx Only
Manufactured for/ Distributed by:
Marlex Pharmaceutical, Inc.
New Castle, DE 19720
Rev.1 12/25 SP
Warnings & precautions
Do not take this medicine if: Sodium polystyrene sulfonate is contraindicated in patients with the following conditions:
Hypersensitivity to polystyrene sulfonate resins
Obstructive bowel disease
Neonates with reduced gut motility
Cases of intestinal necrosis, some fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with sodium polystyrene sulfonate use. The majority of these cases reported the concomitant use of sorbitol. Risk factors for gastrointestinal adverse events were present in many of the cases including prematurity, history of intestinal disease or surgery, hypovolemia, and renal insufficiency and failure. Concomitant administration of sorbitol is not recommended.
Use only in patients who have normal bowel function. Avoid use in patients who have not had a bowel movement post-surgery.
Avoid use in patients who are at risk for developing constipation or impaction (including those with history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction). Discontinue use in patients who develop constipation.
Monitor serum potassium during therapy because severe hypokalemia may occur.
Sodium polystyrene sulfonate is not totally selective for potassium, and small amounts of other cations such as magnesium and calcium can also be lost during treatment. Monitor calcium and magnesium in patients receiving sodium polystyrene sulfonate.
Each 15 g dose of sodium polystyrene sulfonate contains 1500 mg (60 mEq) of sodium. Monitor patients who are sensitive to sodium intake (heart failure, hypertension, edema) for signs of fluid overload. Adjustment of other sources of sodium may be required. …
Sodium Polystyrene Sulfonate side effects
The following adverse reactions are discussed elsewhere in the labeling:
Intestinal Necrosis
Electrolyte Disturbances
Aspiration
The following adverse reactions have been identified during post-approval use of sodium polystyrene sulfonate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure.
Gastrointestinal: anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, ulcerations, vomiting, gastric irritation, intestinal obstruction (due to concentration of aluminium hydroxide)
Metabolic: systemic alkalosis
Drug interactions
No formal drug interaction studies have been conducted in humans.
Sodium polystyrene sulfonate has the potential to bind other drugs. In in vitro binding studies, sodium polystyrene sulfonate was shown to significantly bind the oral medications (n=6) that were tested. Decreased absorption of lithium and thyroxine have also been reported with co-administration of sodium polystyrene sulfonate. Binding of sodium polystyrene sulfonate to other oral medications could cause decreased gastrointestinal absorption and loss of efficacy when taken close to the time sodium polystyrene sulfonate is administered. Administer sodium polystyrene sulfonate at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation. Monitor for clinical response and/or blood levels where possible.
The simultaneous oral administration of sodium polystyrene sulfonate with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis.
Sorbitol may contribute to the risk of intestinal necrosis and concomitant use is not recommended.
About this medicine
Sodium polystyrene sulfonate is a benzene, diethenyl- polymer, with ethenylbenzene, sulfonated, sodium salt and has the following structural formula:
The drug is a golden brown finely ground, powdered form of sodium polystyrene sulfonate, a cation-exchange resin prepared in the sodium phase with an in vitro exchange capacity of approximately 3.1 mEq (in vivo approximately 1 mEq) of potassium per gram. The sodium content is approximately 100 mg (4.1 mEq) per gram of the drug. It can be administered orally or in an enema.
One gram of sodium polystyrene sulfonate contains 4.1 mEq of sodium.
How it works: Sodium polystyrene sulfonate is a non-absorbed, cation exchange polymer that contains a sodium counterion. Sodium polystyrene sulfonate increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 3423d014-4c35-441a-8528-2a7bc050f809. Read the full official label on DailyMed.